Next Article in Journal
Engineering [email protected] Core-Shell Catalysts for Enhanced Electrochemical Oxygen Reduction Mass Activity and Stability
Next Article in Special Issue
Novel Hybrid Formulations Based on Thiourea Derivatives and [email protected] Fe3O4@C18 Nanostructures for the Development of Antifungal Strategies
Previous Article in Journal
Positron Spectroscopy of Nanodiamonds after Hydrogen Sorption
Previous Article in Special Issue
Cationic Biomimetic Particles of Polystyrene/Cationic Bilayer/Gramicidin for Optimal Bactericidal Activity
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Nanomaterials 2018, 8(1), 37;

Gentamicin Sulfate PEG-PLGA/PLGA-H Nanoparticles: Screening Design and Antimicrobial Effect Evaluation toward Clinic Bacterial Isolates

Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, Unit of Microbiology and Clinical Microbiology, University of Pavia, 27100 Pavia, Italy
Author to whom correspondence should be addressed.
Received: 15 December 2017 / Revised: 2 January 2018 / Accepted: 4 January 2018 / Published: 12 January 2018
(This article belongs to the Special Issue Antibacterial Activity of Nanomaterials)
Full-Text   |   PDF [3490 KB, uploaded 12 January 2018]   |  


Nanotechnology is a promising approach both for restoring or enhancing activity of old and conventional antimicrobial agents and for treating intracellular infections by providing intracellular targeting and sustained release of drug inside infected cells. The present paper introduces a formulation study of gentamicin loaded biodegradable nanoparticles (Nps). Solid-oil-in water technique was studied for gentamicin sulfate nanoencapsulation using uncapped Polylactide-co-glycolide (PLGA-H) and Polylactide-co-glycolide-co-Polyethylenglycol (PLGA-PEG) blends. Screening design was applied to optimize: drug payload, Nps size and size distribution, stability and resuspendability after freeze-drying. PLGA-PEG concentration resulted most significant factor influencing particles size and drug content (DC): 8 w/w% DC and 200 nm Nps were obtained. Stirring rate resulted most influencing factor for size distribution (PDI): 700 rpm permitted to obtain homogeneous Nps dispersion (PDI = 1). Further experimental parameters investigated, by 23 screening design, were: polymer blend composition (PLGA-PEG and PLGA-H), Polyvinylalcohol (PVA) and methanol concentrations into aqueous phase. Drug content was increased to 10.5 w/w%. Nanoparticle lyophilization was studied adding cryoprotectants, polyvinypirrolidone K17 and K32, and sodiumcarboxymetylcellulose. Freeze-drying protocol was optimized by a mixture design. A freeze-dried Nps powder free resuspendable with stable Nps size and payload, was developed. The powder was tested on clinic bacterial isolates demonstrating that after encapsulation, gentamicin sulfate kept its activity. View Full-Text
Keywords: nanoparticles; polylactide-co-glycolide; polyethylenglycol; gentamicin sulfate; antimicrobial effect nanoparticles; polylactide-co-glycolide; polyethylenglycol; gentamicin sulfate; antimicrobial effect

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Dorati, R.; DeTrizio, A.; Spalla, M.; Migliavacca, R.; Pagani, L.; Pisani, S.; Chiesa, E.; Conti, B.; Modena, T.; Genta, I. Gentamicin Sulfate PEG-PLGA/PLGA-H Nanoparticles: Screening Design and Antimicrobial Effect Evaluation toward Clinic Bacterial Isolates. Nanomaterials 2018, 8, 37.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top